AU6222496A - Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures - Google Patents

Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures

Info

Publication number
AU6222496A
AU6222496A AU62224/96A AU6222496A AU6222496A AU 6222496 A AU6222496 A AU 6222496A AU 62224/96 A AU62224/96 A AU 62224/96A AU 6222496 A AU6222496 A AU 6222496A AU 6222496 A AU6222496 A AU 6222496A
Authority
AU
Australia
Prior art keywords
ferrites
conjugates
oligonucleotides
certain target
target structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62224/96A
Inventor
Larry Gold
Heinz Gries
Mayk Kresse
Ulrich Niedballa
Detlev Pfefferer
Johannes Dr. Platzek
Bernd Dr. Raduchel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Nexstar Pharmaceuticals Inc
Original Assignee
Schering AG
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG, Nexstar Pharmaceuticals Inc filed Critical Schering AG
Publication of AU6222496A publication Critical patent/AU6222496A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU62224/96A 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures Abandoned AU6222496A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47611695A 1995-06-07 1995-06-07
US476116 1995-06-07
PCT/EP1996/002442 WO1996040273A2 (en) 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures

Publications (1)

Publication Number Publication Date
AU6222496A true AU6222496A (en) 1996-12-30

Family

ID=23890573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62224/96A Abandoned AU6222496A (en) 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures

Country Status (4)

Country Link
JP (1) JPH11507027A (en)
AU (1) AU6222496A (en)
WO (1) WO1996040273A2 (en)
ZA (1) ZA964871B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8507706D0 (en) * 1985-03-25 1985-05-01 Genetics Int Inc Magnetic nucleic acid sequences
DE3709851A1 (en) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te NMR DIAGNOSTIC LIQUID COMPOSITIONS
US4847193A (en) * 1987-06-18 1989-07-11 Gene-Trak Systems Signal amplification in an assay employing a piezoelectric oscillator
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US5516670A (en) * 1991-09-30 1996-05-14 Kuehnle; Adelheid R. Magnetophoretic particle delivery method and apparatus for the treatment of cells
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
DE4424922A1 (en) * 1994-07-14 1996-01-18 Schering Ag Nuclease-resistant oligo:nucleotide conjugates

Also Published As

Publication number Publication date
WO1996040273A2 (en) 1996-12-19
JPH11507027A (en) 1999-06-22
ZA964871B (en) 1997-02-06
WO1996040273A3 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
AU6177796A (en) Initiator system and adhesive composition made therewith
AU5724396A (en) Chemical ligation of template-directed oligonucleotides
AU6208198A (en) Novel modifications of 2-amino-4-(4-flourobenzylamino)-1- ethoxycarbonylaminobenzene, and processes for their preparation
AU5617796A (en) Concrete accelerators
AU8740398A (en) Amplification of nucleic acids
AU6665698A (en) Direct deposition of gold
AU699201B2 (en) Highly fluidized concrete composition
AUPN178995A0 (en) Antigen composition
AU2091799A (en) Uses of alpha-conotoxin peptides
AU5155096A (en) Pharmaceutical composition
AU8583598A (en) Radar absorber and method of manufacture
AU7136196A (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
AU6950096A (en) Methods and compositions for nucleic acid targeting
AU3555295A (en) Game of chance
AU6222496A (en) Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures
EP1001962B8 (en) Production of avermectin compounds
AU2241699A (en) Expression of proteolytically-sensitive peptides
AU7392596A (en) Pressure-assisted formation of shaped articles
AU5131699A (en) Cryogranulation of activated protein c
AU7468196A (en) Conjugates of gonadotropin releasing hormone
AU8842798A (en) Process for the preparation of ivermectin
AUPP385598A0 (en) Purification of antibodies
AU1677100A (en) Localization of software products
AU8869798A (en) Manufacture of thermoset products
AU8102498A (en) Preparation of diaryl-benzopyrans